SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: Implications for hypertension

Hypertension Research

Volumn 36, Issue 10, 2013, Pages 873-878

  Davis, Paul A ^a   Pagnin, Elisa ^b   Dal Maso, Lucia ^b   Caielli, Paola ^b   Maiolino, Giuseppe ^b   Fusaro, Maria ^b   Paolo Rossi, Gian ^b   Calò, Lorenzo A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiovascular remodeling; HO 1; NO dependent vasodilation; SIRT1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HEME OXYGENASE; HEME OXYGENASE 1; HYPERTENSIVE FACTOR; NITRIC OXIDE; SIRTUIN 1;

ADULT; ARTICLE; BARTTER SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GITELMAN SYNDROME; HUMAN; HYPERTENSION; IMMUNOASSAY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MONONUCLEAR CELL; OXIDATIVE STRESS; UPREGULATION; VASODILATATION; WESTERN BLOTTING;

ADULT; BARTTER SYNDROME; BRACHIAL ARTERY; CARDIOVASCULAR SYSTEM; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GITELMAN SYNDROME; HEME OXYGENASE-1; HUMANS; HYPERTENSION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIRTUIN 1; VASODILATION;

EID: 84885138662     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.48     Document Type: Article

References (54)

1. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-1987.
2. Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I, Salvetti A. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29: 736-743.
3. Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin Cardiol 1999; 22: 705-710.
4. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115: 2390-2397.
5. Lind L, Berglund L, Larsson A, Sundström J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation 2011; 123: 1545-1551.
6. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 (Suppl 2), S11-S14.
7. van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios- Callender M, Erusalimsky JD, Quaschning T, Malinski T, Gygi D, Ullrich V, Lü scher TF. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000; 192: 1731-1744.
8. Potente M, Dimmeler SNO, Targets SIRT1. A. Novel Signaling Network in Endothelial Senescence. Arterioscler Thromb Vasc Biol 2008; 28: 1577-1579.
9. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104: 14855-14860.
10. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118.
11. Ota H, Akishita M, Eto M, Iijigima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007; 43: 571-579.
12. Kim YM, Pae HO, Park JE, Lee YC, Woo JM, Kim NH, Choi YK, Lee BS, Kim SR, Chung HT. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010; 14: 137-167.
13. Stocker R, Perrella MA. Heme oxygenase-1. A novel drug target for atherosclerotic diseases? Circulation 2006; 114: 2178-2189.
14. Kalakeche R, Hato T, Rhodes G, Dunn KW, El-Achkar TM, Plotkin Z, Sandoval RM, Dagher PC. Endotoxin uptake by S1 proximal tubular segment causes oxidative stress in the downstream S2 segment. J Am Soc Nephrol 2011; 22: 1505-1516.
15. Ali F, Ali NS, Bauer A, Boyle JJ, Hamdulay SS, Haskard DO, Randi AM, Mason JC. PPARd and PGC1a act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. Cardiovasc Res 2010; 85: 701-710.
16. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96: 65-78.
17. Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 2010; 56: 325-330.
18. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005; 23: 1831-1837.
19. Calo LA. Vascular tone control in humans: the utility of studies in Bartter's/Gitelman's syndromes. Kidney Int 2006; 69: 963-966.
20. Calo L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, D'Angelo A. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51: 12-17.
21. Calo L, D'Angelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, Borsatti A. Increased urinary NO2-/NO3- and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874-879.
22. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, Zambon S, Cantaro S, D'Angelo A, Davis PA, Manzato E, Crepaldi G. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16: 1001-1008.
23. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518-1525.
24. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23: 2804-2809.
25. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006; 29: 469-471.
26. Calò LA, Facco M, Davis PA, Pagnin E, Maso LD, Puato M, Caielli P, Agostini C, Pessina AC. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res 2011; 34: 1017-1022.
27. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P, Semplicini A, Palatini P, D'Angelo A, Pessina AC. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009; 32: 832-836.
28. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metabol 2004; 89: 4153-4157.
29. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, Pessina AC. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: Insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26: 938-945.
30. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25: 259-264.
31. Calò LA, Davis PA, Pagnin E, Dal Maso L, Caielli P, Rossi GP. Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. J Hypertens 2012; 30: 1406-1413.
32. Kao CL, Chen LK, Chang YL, Yung MC, Hsu CC, Chen YC, Lo WL, Chen SJ, Ku HH, Hwang SJ. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J Atheroscler Thromb 2010; 17: 970-979.
33. Csiszar A, Labinskyy N, Jimenez R, Pinto JT, Ballabh P, Losonczy G, Pearson KJ, de Cabo R, Ungvari Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev 2009; 130: 518-527.
34. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008; 80: 191- 199.
35. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, Zhang C, Mukhopadhyay P, Pacher P, Hu F, de Cabo R, Ballabh P, Ungvari Z. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008; 294: H2721-H2735.
36. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 2011; 589: 4545-4554.
37. Rippe C, Lesniewski L, Connell M, LaRocca T, Donato A, Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell 2010; 9: 304-312.
38. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148: 421-433.
39. Stoff JS, Stemerman M, Steer M, Salzman E, Brown RS. A defect in platelet aggregation in Bartter's syndrome. Am J Med 1980; 68: 171-180.
40. Xie Z, Liu D, Liu S, Calderon L, Zhao G, Turk J, Guo Z. Identification of a cAMPresponse element in the regulator of G-protein signaling-2 (RGS2) promoter as a key cis-regulatory element for RGS2 transcriptional regulation by angiotensin II in cultured vascular smooth muscles. J Biol Chem 2011; 286: 44646-44658.
41. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos- Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003; 111: 445-452.
42. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E, Strapazzon G, Benna C, Costa R, Avogaro A, Ceolotto G, Pessina AC. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24: 1115-1124.
43. Tsingotjidou A, Nervina JM, Pham L, Bezouglaia O, Tetradis S. Parathyroid hormone induces RGS-2 expression by a cyclic adenosine 3',5'-monophosphate- mediated pathway in primary neonatal murine osteoblasts. Bone 2002; 30: 677-684.
44. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
45. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension 2001; 37 (part 2), 594-598.
46. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
47. Dhalla NS, Temsha RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655-673.
48. Avogaro A, Pagnin E, Calo L. Monocyte NADPH oxidase subunit p22(phox) and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: Relationship with oxidative stress. J Clin Endocrinol Metab 2003; 88: 1753-1759.
49. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Lü scher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
50. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappa B signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25: 904-914.
51. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
52. Calò LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC. Linking inflammation and hypertension in humans: studies in Bartter's/Gitelman's syndrome patients. J Hum Hypertens 2008; 22: 223-225.
53. de Kreutzenberg SV, Ceolotto G, Papparella I, Bortoluzzi A, Semplicini A, Dalla Man C, Cobelli C, Fadini GP, Avogaro A. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010; 59: 1006-1015.
54. Fröjdö S, Durand C, Molin L, Carey AL, El-Osta A, Kingwell BA, Febbraio MA, Solari F, Vidal H, Pirola L. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol 2011; 335: 166-176.